ReNeu: A Pivotal Phase 2b Trial of Mirdametinib in Children and Adults With Neurofibromatosis Type 1 (NF1)-Associated Symptomatic Plexiform Neurofibroma (PN) (S29.003)
ReNeu (NCT03962543) is a pivotal, phase 2b trial evaluating efficacy and safety of mirdametinib (investigational MEK1/2 inhibitor) in adults and children (≥2y) with symptomatic inoperable NF1-PN.
Authors
- Kevin Bielamowicz (ORCID: https://orcid.org/0000-0003-0790-2931)
- Rene McNall‐Knapp (ORCID: https://orcid.org/0000-0002-0416-7364)
- Hans Shuhaiber
- L. Mary Smith
- Alpa Sidhu (ORCID: https://orcid.org/0000-0002-8980-5029)
- Nicholas K. Foreman (ORCID: https://orcid.org/0000-0003-4848-4801)
- Armend Lokku
- Michael Weber (ORCID: https://orcid.org/0000-0002-8507-2219)
- Angela C. Hirbe (ORCID: https://orcid.org/0000-0003-1719-0771)
- David H. Viskochil (ORCID: https://orcid.org/0000-0001-5364-3366)
- Lauren Weintraub (ORCID: https://orcid.org/0009-0009-4406-1255)
- Dusica Babovic‐Vuksanovic (ORCID: https://orcid.org/0000-0001-6981-1352)
- Fouad Hajjar
- Timothy R. Gershon (ORCID: https://orcid.org/0000-0001-7034-6400)
- Christopher L. Moertel (ORCID: https://orcid.org/0000-0002-5474-588X)
Institutions
- Arkansas Children's Hospital (US)
- Emory University (US)
- University of Utah (US)
- University of Minnesota System (US)
- University of Iowa Hospitals and Clinics (US)
- WinnMed (US)
- University of Florida (US)
- Children's Hospital Colorado (US)
- AdventHealth for Children (US)
- Meridien Research (US)
- University of Oklahoma Health Sciences Center (US)
- Albany Medical Center Hospital (US)
- University of Arkansas for Medical Sciences (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000209005
- Primary Topic
- Neurofibromatosis and Schwannoma Cases
- Type
- article
- Field-Weighted Citation Impact
- 0.00